USE OF NEBIVOLOL IN PREGNANCY
Date of issue: July 2024, Version: 4
Nebivolol is a cardioselective beta-blocker licensed for the treatment of hypertension and chronic heart failure.
A single, small study found no adverse effects on fetal growth following in utero exposure to nebivolol. Further research is required to confirm this finding, particularly given that beta-blocker class data have suggested exposure is associated with reduced fetal growth. There are no further studies assessing the risks of adverse pregnancy outcomes following gestational exposure to nebivolol.
Studies of beta-blockers as a class do not show that use during pregnancy is associated with fetal structural malformation. Use of beta-blockers in pregnancy has been associated with adverse effects on fetal growth; however, maternal hypertension is linked to intrauterine growth restriction, therefore, the relative contribution of beta-blocker exposure to this outcome remains unquantified. Overall, data do not suggest that gestational beta-blocker exposure increases the risk of preterm delivery. Data on rates of miscarriage, stillbirth and neurodevelopmental outcomes are too limited to permit a risk assessment.
Use of beta-blockers near term may result in neonatal beta-adrenoceptor blockade, leading to neonatal bradycardia, hypotension and hypoglycaemia. Respiratory distress has also been reported. Assessment of the neonate for these effects is advised. There is a single case report of a term infant exposed to nebivolol during the final four months of pregnancy with neonatal hypoglycaemia, jaundice, polycythaemia, mild thrombocytopenia and hyponatremia. Due to the nature of this report, causality cannot be ascribed to nebivolol exposure.
Exposure to nebivolol at any stage in pregnancy would not be regarded as medical grounds for termination of pregnancy. Additional fetal monitoring is generally indicated in pregnancies complicated by hypertension and/or maternal cardiac disease, regardless of pharmacotherapy. Additional growth scans should be offered following gestational exposure to beta-blockers. Other risk factors may be present in individual cases which may independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.
Related document: Use of beta blockers in pregnancy
This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.
If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.
If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.